What is Milestone Pharmaceuticals?
Milestone Pharmaceuticals is a specialized biopharmaceutical entity dedicated to the research, development, and advancement of innovative cardiovascular therapies. The company focuses primarily on heart rhythm disorders, leveraging clinical research to provide effective treatment options that improve patient outcomes. By collaborating with healthcare professionals and research partners, Milestone operates at the intersection of biotechnology and cardiology, aiming to solve complex medical challenges through targeted therapeutic solutions. Its market position is defined by a commitment to scientific rigor and a strategic focus on high-impact cardiovascular conditions.
How much funding has Milestone Pharmaceuticals raised?
Milestone Pharmaceuticals has raised a total of $412.5M across 8 funding rounds:
Series A
$13M
Series B
$17M
Series C
$55M
Series D
$80M
Stock Offering
$94.9M
Share Placement
$25M
Other Financing Round
$125M
Series A (2011): $13M led by Fonds de Solidarité FTQ, Business Development Bank of Canada, Pappas Ventures, GO Capital, iNovia Healthcare Ventures, and Fonds Bio-Innovation
Series B (2015): $17M supported by Pappas Ventures, Inovia, Domain Associates, Fonds de solidarité FTQ, GO Capital, and BDC Capital
Series C (2017): $55M featuring Fonds de solidarité FTQ, GO Capital, Tekla Capital Management, Novo Holdings, Pappas Capital, Forbion, Domain Associates, and BDC Capital
Series D (2018): $80M backed by Domain Associates, Forbion, BDC Capital, Boxer Capital, RTW Investments, Novo Holdings, Fonds de solidarité FTQ, GO Capital, Venrock Healthcare Capital Partners, Tekla Capital Management, and Pappas Capital
Stock Issuance/Offering (2019): $94.9M, investors not publicly disclosed
Share Placement (2020): $25M led by RTW Investments , LP
Other Financing Round (2023): $125M supported by RTW Investments
Key Investors in Milestone Pharmaceuticals
Pappas Capital
Pappas Capital is a leading healthcare venture capital firm that specializes in advancing biopharma, biotech, and medical technologies aimed at improving patient outcomes.
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments with a focus on biopharmaceutical, device, and diagnostic companies.
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, from company creation to public companies.
What's next for Milestone Pharmaceuticals?
Looking ahead, the strategic deployment of the $125M will likely focus on the maturation of the company's clinical pipeline and the expansion of its research capabilities. As Milestone Pharmaceuticals moves deeper into its lifecycle, the focus will shift toward regulatory milestones and the potential commercialization of its lead candidates. The continued involvement of top-tier life sciences investors suggests a long-term commitment to scaling the company's impact on global cardiovascular health. Future growth will be contingent upon the successful execution of clinical programs and the ability to maintain a competitive edge in the rapidly evolving biopharmaceutical landscape.
See full Milestone Pharmaceuticals company page
